The increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
Tyler Beardslee, PharmD, BCOP
Advertisement
Articles by Tyler Beardslee, PharmD, BCOP
Advertisement
Latest Updated Articles
Management of Steroid-Refractory Immune-Related Adverse EventsPublished: August 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
3
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
4
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
5
